You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

CD19 Positive Disease

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Mixed Phenotype Acute Leukemia (MPAL), Measurable Residual Disease (MRD) Trial in Baltimore (BLINCYTO (Blinatumomab))

Recruiting
  • Mixed Phenotype Acute Leukemia (MPAL)
  • Measurable Residual Disease (MRD)
  • BLINCYTO (Blinatumomab)
  • Baltimore, Maryland
    Greenebaum Cancer Center at University of Maryland Medical Cente
Apr 18, 2022

Non-Hodgkin's Lymphoma (Disorder), Acute Lymphoid Leukemia, Disease (Disorder) Trial in Louisville, Houston (1A46 Injection)

Recruiting
  • Non-Hodgkin's Lymphoma (Disorder)
  • Acute Lymphoid Leukemia, Disease (Disorder)
  • 1A46 Injection
  • Louisville, Kentucky
  • +1 more
Aug 1, 2022

Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Juvenile Myelomonocytic Leukemia Trial (Miltenyi CliniMACS Prodigy ®

Not yet recruiting
  • Acute Lymphoblastic Leukemia
  • +6 more
  • Miltenyi CliniMACS Prodigy ® system
  • (no location specified)
Mar 23, 2023

CD19-positive Relapsed or Refractory B-cell Malignancies Trial in Hefei (UTAA09 cells for infusion, Fludarabine,

Not yet recruiting
  • CD19-positive Relapsed or Refractory B-cell Malignancies
  • UTAA09 cells for infusion
  • +2 more
  • Hefei, Anhui, China
    The First Affiliated Hospital of USTC (AnHui Provincial Hospital
Oct 13, 2023

Acute Lymphoblastic Leukemia Trial in Hangzhou (Blinatumomab)

Recruiting
  • Acute Lymphoblastic Leukemia
  • Hangzhou, Zhejiang, China
    The first affiliated hospital of medical college of zhejiang uni
Nov 5, 2023

Acute Lymphoblastic Leukemia, in Relapse, Non-Hodgkin's Lymphoma, Relapsed, Non-Hodgkin's Lymphoma Refractory Trial in Columbus

Not yet recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +5 more
  • CD19 specific Chimeric Antigen Receptor T Cell
  • Columbus, Ohio
    Nationwide Children's Hospital
Mar 9, 2023

Non-hodgkin Lymphoma, Acute Lymphoblastic Leukaemia, Chronic Lymphocytic Leukemia Trial in Tianjin (CC312)

Recruiting
  • Non-hodgkin Lymphoma
  • +2 more
  • CC312
  • Tianjin, Tianjin, China
    InstituteHBDH
Sep 12, 2023

Acute Lymphoblastic Leukemia Trial in Sanhe (CAR-NK-CD19 Cells)

Completed
  • Acute Lymphoblastic Leukemia
  • CAR-NK-CD19 Cells
  • Sanhe, Hebei, China
    Hebei Yanda Ludaopei Hospital
Nov 24, 2022

Advanced Malignancies Trial in Beijing (1A46 Drug Substance)

Not yet recruiting
  • Advanced Malignancies
  • 1A46 Drug Substance
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Aug 4, 2023

R/R CD19-Positive B-Cell Malignancies, Indolent Non-Hodgkin Lymphoma, Aggressive Non-Hodgkin Lymphoma Trial (CNTY-101, IL-2,

Recruiting
  • R/R CD19-Positive B-Cell Malignancies
  • +2 more
  • CNTY-101
  • +2 more
  • Detroit, Michigan
  • +1 more
Dec 21, 2022

SLE (Systemic Lupus), Sjogren's Syndrome, Systemic Scleroderma Trial in Taiyuan (CD19 targeted CAR-T cells)

Recruiting
  • SLE (Systemic Lupus)
  • +4 more
  • CD19 targeted CAR-T cells
  • Taiyuan, Shanxi, China
    Shanxi Bethune Hospital
Sep 25, 2023

Graft Vs Host Disease, Graft-versus-host-disease, Acute Myeloid Leukemia Trial (CliniMACS® device)

Not yet recruiting
  • Graft Vs Host Disease
  • +5 more
  • CliniMACS® device
  • (no location specified)
Jul 20, 2023

Acute Lymphoblastic Leukemia in Remission Trial in Suzhou (CD19 CAR-T cells and CD19 positive feeder T cells)

Recruiting
  • Acute Lymphoblastic Leukemia in Remission
  • CD19 CAR-T cells and CD19 positive feeder T cells
  • Suzhou, Jiangsu, China
  • +2 more
May 18, 2022

Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia, Refractory, Pediatric ALL Trial in Memphis (biological,

Recruiting
  • Acute Lymphoblastic Leukemia, in Relapse
  • +2 more
  • CD19-CAR(Mem) T-cells
  • +5 more
  • Memphis, Tennessee
    St. Jude Children's Research Hospital
Aug 5, 2022

Recurrent DLBCL, Refractory Diffuse Large B-cell Lymphoma Trial in Tianjin (RC19D2 cell injection)

Recruiting
  • Recurrent Diffuse Large B-Cell Lymphoma
  • Refractory Diffuse Large B-cell Lymphoma
  • RC19D2 cell injection
  • Tianjin, Tianjin, China
    Hematology Hospital of the Chinese Academy of Medical Sciences
Sep 14, 2023

Lymphoma, Non-Hodgkin, Lymphoma, B-Cell, Chronic Lymphocytic Leukemia Trial in Milwaukee (CAR-20/19-T cells (1.0 x10^5

Completed
Has Results
  • Lymphoma, Non-Hodgkin
  • +3 more
  • CAR-20/19-T cells (1.0 x10^5 CAR-20/19-T cells/kg)
  • +3 more
  • Milwaukee, Wisconsin
    Froedtert Hospital & Medical College of Wisconsin
Jun 26, 2022

Prior Blinatumomab on Subsequent CD19 CAR Outcomes and

Active, not recruiting
  • Leukemia, Acute Lymphoblastic
  • Lymphoblastic Leukemia, Acute, Childhood
    • Bethesda, Maryland
      National Cancer Institute (NCI)
    Aug 13, 2022

    B-Cell Lymphoblastic Leukemia, Acute Lymphoblastic Leukemia Trial in Tampa (Tecartus)

    Recruiting
    • B-Cell Lymphoblastic Leukemia
    • Acute Lymphoblastic Leukemia
    • Tampa, Florida
      Moffitt Cancer Center
    Nov 28, 2023

    Lymphomas Non-Hodgkin's B-Cell, Relapse Trial in Tianjin (CD19 CAR T cells)

    Completed
    • Lymphomas Non-Hodgkin's B-Cell
    • Relapse
    • CD19 CAR T cells
    • Tianjin, China
      Institute of Hematology & Blood Diseases Hospital
    Jan 24, 2022

    Philadelphia Chromosome-negative or BCR-ABL-negative, CD19-positive ALL Trial in Spain (blinatumomab)

    Terminated
    • Philadelphia Chromosome-negative or BCR-ABL-negative, CD19-positive ALL
    • Badalona, Barcelona, Spain
    • +11 more
    Jul 26, 2022

    Relapsed or Refractory Acute Lymphoblastic Leukemia Trial in Shanghai (ssCART-19 Cells, Fludarabine, Cyclophosphamide)

    Recruiting
    • Relapsed or Refractory Acute Lymphoblastic Leukemia
    • ssCART-19 Cells
    • +2 more
    • Shanghai, Shanghai, China
      Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd.
    May 17, 2022

    Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia Refractory, B-cell Lymphoma Recurrent Trial in São Paulo

    Not yet recruiting
    • Acute Lymphoblastic Leukemia, in Relapse
    • +5 more
    • São Paulo, Brazil
      Hospital Israelita Albert Einstein
    Jan 20, 2023

    Acute Lymphoblastic Leukemia, CD19 Positive, Relapse Trial in Suzhou (Humanized CD19 CAR-T cells, Humanized CD19 CAR-T cells

    Recruiting
    • Acute Lymphoblastic Leukemia
    • +3 more
    • Humanized CD19 CAR-T cells
    • Humanized CD19 CAR-T cells with CRS suppression technology
    • Suzhou, Jiangsu, China
      The first affiliated hospital of soochow university
    May 18, 2022

    Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL, Refractory Acute Lymphoblastic Leukemia Trial in China (pCAR-19B cells)

    Recruiting
    • Acute Lymphoblastic Leukemia
    • +2 more
    • pCAR-19B cells
    • Beijing, Beijing, China
    • +9 more
    May 19, 2022

    CD19-positive, Acute Lymphoblastic Leukemia Trial in Shanghai (Human CD19 targeted T Cells Injection)

    Recruiting
    • CD19-positive
    • Acute Lymphoblastic Leukemia
    • Human CD19 targeted T Cells Injection
    • Shanghai, Shanghai, China
      Shanghai General Hospital
    Aug 29, 2021